Skip to main content

Table 2 Medications for HBV and HCV patients in the initial 6 months after anti-hypertensive treatment (grouped by use of angiotensin converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARB] in the initial 6 months after index date)

From: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study

  

HBV patients

  

HCV patients

 

Variables

All

Initial exposure

Initial non-exposure

All

Initial exposure

Initial non-exposure

n

7724

3575

4149

7873

3349

4524

ACEI (%)

13.4

28.9*

0

12.5

29.5*

0

 Cumulative DDDa

168 (84–205)

168 (84–205)

0

168 (95–200)

168 (95–200)

0

ARB (%)

36.6

79.0*

0

32.5

76.5*

0

 Cumulative DDDa

168 (87–198)

168 (87–198)

0

168 (98–196)

168 (98–196)

0

Aspirin (%)

18.8

23.2*

15.0

19.8

26.5*

14.9

 Cumulative DDDa

308 (97–392)

309 (130–400)

284 (84–386)

330 (142–420)

336 (168–420)

309 (120–420)

Metformin (%)

19.0

24.4*

14.4

19.2

26.6*

13.7

 Cumulative DDDa

84 (39–126)

88 (42–133)

75 (31–105)

89 (51–133)

90 (57–135)

84 (45–126)

Statin (%)

12.5

17.1*

8.6

5.9

8.4*

4.1

 Cumulative DDDa

74 (37–112)

73 (37–112)

75 (30–112)

70 (37–112)

68 (37–112)

75 (35–112)

  1. aData are median (Q1-Q3). *p < 0.05 between initial exposure and non-exposure groups. DDD defined daily dose